08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On February 4, 2020, the Pension Benefit Guaranty Corporation (“PBGC”) issued final regulations (t...
Read More >
The Relationship Between Sickness and Paid Holiday Leave to Suspend the Period of Retention of Emplo...
Read More >
Misclassification of employees as independent contractors "does not violate the [National Labor Rela...
Read More >
CONVERGE19 is in its 4th year of bringing together the world’s leading companies for 2 days of dyna...
Read More >
Plan sponsors are typically aware that operational errors threaten a retirement plan’s qualified st...
Read More >
The Chancellor of the Exchequer has announced in the 2020 Budget that the government "will invest an...
Read More >